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Purpose:  To  investigate  whether  vector-based  vascular  endothelial  growth  factor  165  (VEGF)165  targeted  siRNA
expression system (pSilencersiVEGF) could inhibit VEGF165 expression in vitro and suppresses retinal neovascularization
in the murine model of oxygen-induced retinopathy.
Methods: pSilencersiVEGF, from which siRNA targeting VEGF165 could be generated, was constructed and transfected to
human umbilical vein endothelial cells. Then the level of VEGF isoforms in cultured cells was measured by RT–PCR and
ELISA.  Intravitreal  injection  of  pSilencersiVEGF  was  performed  in  mice  with  ischemic  retinopathy.  Retinal
neovascularization was evaluated by angiography using fluorescein-labeled dextran and quantitated histologically. The
levels of VEGF164, which is equivalent to human VEGF165 in murine retinas were determined by RT–PCR and western
immunoblotting.
Results: Expression of VEGF165 in cultured cells was greatly curtailed by pSilencersiVEGF under both normoxia and hypoxia
conditions. However, the other isoforms, VEGF189 and VEGF121, were expressed to a similar degree regardless of whether
pSilencersiVEGF was administered. Based on angiography and histological analysis, retinal neovascularization in the eyes
treated with pSilencersiVEGF were significantly reduced compared to the control eyes. Furthermore, the VEGF164 levels in
the murine retinas were suppressed by pSilencersiVEGF.
Conclusions: Retinal neovascularization in the murine model was significantly attenuated by pSilencersiVEGF through
decreasing VEGF164 levels in the retinas. pSilencersiVEGF seems to be a potential therapeutic tool for ischemic-induced
retinal diseases.
Retinal neovascularization, abnormal formation of new
vessels from preexisting capillaries in the retina, is a common
complication  of  many  ocular  diseases,  such  as  advanced
diabetic  retinopathy,  and  retinopathy  of  prematurity.
Neovascularization  can  lead  to  fibrosis  and  disruption  of
delicate tissues required for vision. Laser photocoagulation as
conventional treatment is effective in halting the progression
of  angiogenesis  in  the  short-term.  However,  it  is  also
destructive  to  the  retinal  tissue,  leads  to  immediate  and
sometimes significant loss of vision, and does not address the
underlying angiogenic mechanisms of the disease. Therefore,
therapy targeting molecular mechanisms underlying retinal
neovascularization may provide better treatment result and
fewer detrimental side effect.
Angiogenesis is a complex process, involving multiple
gene  products  expressed  by  different  cell  types,  all
contributing to an integrated sequence of events. However,
laboratory  studies  have  demonstrated  that  vascular
endothelial  growth  factor  (VEGF)  plays  a  central  role  in
several  retinal  vascular  diseases.  Clinical  trials  have
confirmed the importance of VEGF in disease pathogenesis
[1,2]. Consequently, VEGF becomes an optimal target for
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inhibition  of  retinal  neovascularization.  Accumulated  data
indicate that attenuation of VEGF activity could effectively
suppress retinal neovascularization. Recent treatments based
on antibody technology have been proven to be efficacious.
Lucentis, a anti-VEGF antibody fragment, has been approved
as  an  antiangiogenic  drug  for  the  treatment  of  ocular
neovascularization  [3].  Although  antibodies  are  effective,
they are not efficient. Large amounts of antibodies are needed
to suppress the targeted protein, and the inhibitory effects of
antibodies  are  transient  unless  these  high  doses  are
administered repeatedly.
RNA  interference  (RNAi)  is  a  recently  developed
technique to silence proteins in a sequence-specific manner
by  inhibiting  mRNA  and  consequently  reducing  protein
expression. The high efficiency and specificity of RNAi has
made it a powerful and widely used tool for gene therapy. The
functional mediator of RNAi is a short double strand RNA
(dsRNA)  oligonucleotide  called  small  interfering  RNA
(siRNA)  [4].  A  growing  number  of  investigations  are
examining the use of siRNA as a candidate therapeutic agent,
Currently,  there  are  two  siRNA-based  molecules:  Cand5,
which  is  a  siRNA  against  all  isoforms  of  VEGF,  and
siRNA-027, a kind of siRNA targeting VEGF receptor 1 [5].
Acuity Pharmaceuticals (Philadelphia, PA) has begun a Phase
II  clinical  trial  for  Cand5,  and  Sirna  Therapeutics  (San
Francisco, CA) is on a Phase 1 clinical trial for siRNA-027.
However, due to differential pre-mRNA splicing, a single
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1965VEGF gene gives rise to many different VEGF isoforms. To
date, five isoforms of human VEGF have been identified:
VEGF121,  VEGF145,  VEGF165,  VEGF189,  and  VEGF206  [6].
Although VEGF is highly conserved throughout evolution,
the  murine  homologs  contain  one  fewer  amino  acid.  The
murine designation for the human VEGF165 is VEGF164. Of the
various isoforms, VEGF165 (VEGF164) appears to be the major
pathological  VEGF  isoform  in  the  eye  [7].  Because
VEGF165 is a major disease-causing isoform in models of
neovascular  eye  disease,  we  expected  to  identify  whether
retinal angiogenesis could be attenuated by siRNA targeting
VEGF165.
In this report, we used a vector-based siRNA expression
system, which overcomes the limitations of transience and
high  cost  in  synthetic  siRNAs,  to  specifically  inhibit
VEGF165  expression  in  the  murine  model  of  proliferative
retinopathy.  Our  data  confirm  the  potential  VEGF165
inhibitors for the treatment of ocular angiogenesis.
METHODS
Recombinant  pSilencersiVEGF  construction:  The  cDNA
oligonucleotides targeting VEGF165 mRNA were designed
and examined by Guan et al. [13]. A pair of 63 nucleotide
oligos containing endonuclease restriction sites at both ends
was synthesized by the Sangong Company (Shanghai, China).
The sequences used were: First strand-5′–GAT CCG ATA
GAG CAA GAC AAG AAA TTC AAG AGA TTT CTT GTC
TTG CTC TAT CTT TTT TGG AAA–3′; Second strand-5′–
AGC TTT TCC AAA AAA GAT AGA GCA AGA CAA
GAA ATC TTT GAA TTT CTT GTC TTG CTC TAT CG–
3′ (complementary sequence is indicated in red). The annealed
dsDNA oligonucleotides were ligated between the BamHI
and HindIII sites on the pSilencer2.1-U6 hygro vector. The
targeted VEGF165 sequences were GAT AGA GCA AGA
CAA GAA A. All inserted sequences were confirmed by
DNA sequencing.
Cell culture and transfection of cells: Human umbilical vein
endothelial cell lines (HUVECs) were purchased from the
American  Type  Culture  Collection  (Manassas,  VA).
HUVECs were grown in F12K medium, containing 0.1 mg/
ml heparin, 20% fetal bovine serum, 0.03 mg/ml endothelial
cell growth supplement (BD Biosciences, San Jose, CA), and
antibiotic mixtures of 100 U/ml penicillin G and 100 μg/ml
streptomycin sulfate. Cells were cultured in an incubator at
37 °C in an atmosphere of 95% air and 5% CO2. In the vitro
studies,  an  oxygen  concentration  of  20%  was  considered
normoxic.  Hypoxia  was  1%  oxygen.  In  the  vivo  studies,
normoxic mice were raised in room-air-raised. For hyperoxia,
mice  were  kept  in  75±2%  oxygen.  Transfection  reagent
lipofectamine2000 was used to transfer the pSilencersiVEGF to
the  HUVECs  according  to  the  manufacturer’s  protocol
(Invitrogen, Carlsbad, CA). In brief, 2×105 HUVECs cells
were  seeded  into  six-well  plates.  A  2.5:1  ratio  of
lipofectamine–pSilencersiVEGF  (Invitrogen)  complexes  were
prepared and added to the HUVECs.
Reverse transcription and polymerase chain reaction: Whole
RNA of cultured cells or murine retinas were isolated with
TRIzol® reagent (Invitrogen). Total RNA was isolated using
Trizol  reagents  (Gibco-BRL  Life  Technologies,  Gibco,
Carlsbad, CA), followed by treatment for 45 min with RNase-
free DNase at 37 °C (Message Clean; GeneHunter Corp.,
Nashville,  TN),  phenol:chloroform  (ratio  1:1)  extraction,
ethanol precipitation, and stabilizing in DEPC-treated water.
RNA concentration was determined by spectrophotometric
readings at 260 and 280 nm. Each 2 mg of RNA extract was
reverse-transcribed  into  cDNA  with  RevertAidTM  First
Strand cDNA Synthesis Kit (MBI, Burlington, MD). PCR was
performed  in  50  µl  of  a  solution  containing  Taq  DNA
polymerase, dNTP, VEGF primer, or β-actin primer and RT
products. The primer pair, 5′-CGA AGT GGT GAA GTT
CAT GGA TG-3′ (sense) and 5′-TTC TGT ATC AGT CTT
TCC TGG TGA G-3′ (antisense), was used to amplify human
VEGF isoforms in cultured cells. The primer pair, 5′-CCT
CCG AAA CCA TGA ACT TTC TGC TC-3′ (sense) and 5′-
CAG CCT GGC TCA CCG CCT TGG CTT-3′ (antisense),
was designed to yield the PCR products of murine VEGF
isoforms. The primer pair, 5′ CGT TGA CAT CCG TAA
AGA C 3′ (sense) and 5′ TGG AAG GTG GAC AGT GAG
3′ (antisense), was used to obtain the PCR product of β-actin.
After  a  preincubation  for  5  min  at  94  °C,  30  cycles  of
amplification (94 °C for 45 s, 60 °C for 45 s, and 72 °C for 45
s) were performed, and β-actin was used as an internal control.
Amplified products were run in a 1.5% ethidium bromide
agarose gel, band intensities were captured with a ChemiDoc
system  and  LabWorks  software  (UVP,  Upland,  CA),  and
values were transferred to an Excel spreadsheet for calculation
of means and standard errors.
ELISA  assay  for  VEGF  production:  The  medium  from
normoxia  and  hypoxia  cultured  cells  was  collected,
centrifuged  at  750×g  for  5  min,  and  stored  at  −70  °C.
Concurrently,  cells  were  trypsinized  and  counted.  The
concentration of the secreted VEGF165 isoform in the media
was  determined  with  an  ELISA  kit  (R&D  Systems,
Minneapolis,  MN)  according  to  the  manufacturer’s
instructions and was expressed as pg VEGF/105 cells.
Animal model of proliferative retinopathy: The study protocol
conformed to the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research. The reproducible murine
model  of  oxygen-induced  retinopathy  (OIR)  has  been
described previously [8]. C57BL/6J mice were bought from
Experimental Animal Center of Central South University,
Changsha, Hunan province, China. The mice were exposed to
less than 300 lx of 12 h cyclical broad spectrum light. The
oxygen-treated mice were housed in an incubator. Oxygen
concentration  was  monitored  with  a  Beckman  oxygen
analyzer  (Model  D2;  Beckman,.  Irvine,  CA).  The  cage
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1966temperature was maintained at 23 °C±2 °C. The mice were
placed in the oxygen chamber with enough food and water to
sustain them for 5 days. Postnatal day 7 (P7) C57BL/6J mice
and their nursing mothers were exposed to 75%±2% oxygen
for  five  days.  On  P12,  the  mice  were  removed  from  the
chamber and maintained in room air until P17. Mice of the
same strain and of the same age were kept in room air and
used as control subjects. Intravitreal injections of liposome–
pSilencersiVEGF complexes were performed at P12 as described
in the next section. At P17, the mice were sacrificed by cardiac
perfusion  of  4%  paraformaldehyde  in  phosphate-buffered
saline (PBS) catalog number of PBS is 20012043 (Gibco), and
their  eyes  were  enucleated  for  RT–PCR  and
immunohistologic  analysis.  Alternatively,  some  mice
underwent retinal fluorescein angiography, as described in the
next section.
Intravitreal  injections:  At  P12,  mouse  pups  were  deeply
anesthetized  with  a  30  mg/kg  intraperitoneal  injection  of
sodium pentobarbital. The lid fissure was opened with a no.
11  scalpel  blade,  and  the  eye  was  proptosed.  Intravitreal
injections were performed by first entering the eye with an
Ethicon TG140–8 suture needle at the posterior limbus. A 32-
gauge Hamilton needle and syringe were used to deliver 1 µl
liposome-pSilencersiVEGF complex (0.5 µl liposome and 1–
1000 ng of pSilencersiVEGF) or 1 µl control complex (0.5 µl
liposome and 0.5 µl of 2 mg/ml pSilencer null vector) into the
vitreous cavity.
Angiography  with  high-molecular-weight  fluorescein-
dextran: At P17, mice were anesthetized with a 30 mg/kg
intraperitoneal injection of sodium pentobarbital sodium, and
cardiac perfusion was performed with 1 ml PBS containing
50  mg/ml  fluorescein-labeled  dextran  (2×106  average
molecular  weight;  Sigma,  St  Louis,  MO),  clarified  by
centrifugation for 5 min at 10,600 xg. Subsequently, the mice
were sacrificed, and their eyes were enucleated. The retinas
were dissected and flatmounted on microscope slides with
glycerol gelatin.
Histological  analysis  of  neovascularization:  The  eyes  of
sacrificed P17 mice were enucleated, fixed overnight with 4%
paraformaldehyde in PBS, and embedded in paraffin. Half of
the  group  of  mice  were  used  for  angiography  with  high-
molecular-weight fluorescein-dextran, and the other half were
used for histological analysis of neovascularization. Paraffin-
embedded axial serial sections of the retina, 6 µm thick, were
obtained starting at the optic nerve head. After staining with
periodic acid-Schiff reagent and hematoxylin, we evaluated
10 intact sections of equal length, each 30 µm apart, for a span
of 300 µm. All retinal vascular cell nuclei anterior to the
internal  limiting  membrane  were  counted  in  each  section
according to a masked protocol. The mean of all ten counted
sections  yielded  average  neovascular  cell  nuclei  per  6μm
section per eye.
Western blot analysis of VEGF in the murine retina: The
murine  retinas  were  collected  and  lysed  in  lysis  buffer
composed of 150 mmol/l NaCl, 50 mmol/l Tris-HCl, pH 7.4,
2 mmol/l EDTA, and 1% NP-40 that also contained protease
inhibitors  (Boehringer  Mannheim,  Mannheim,  Germany).
Total  protein  (30  μg  per  lane)  was  loaded  on  SDS-
polyacrylamide  gel  and  transferred  onto  a  nitrocellulose
membrane and incubated with a 1:500 dilution rat monoclonal
anti-VEGF antibody Santa Cruz (Santa Cruz, CA, catalog
number sc-80436) and a 1:10,000 dilution mouse monoclonal
anti-β-actin antibody (Sigma, St. Louis, MO), followed by
incubation  with  corresponding  secondary  antibodies
(peroxidase conjugated). The enhanced chemiluminescence
(ECL)  chemiluminescence  reagent  was  added  to  the
membrane according to the manufacturer’s directions. The
membrane was exposed to an X-ray film for 1 min before it
was developed and fixed. Images of blots were entered into a
computer  using  a  scanner  (Epson,  Nagano,  Japan)  and
analyzed  using  LabWorks  Software  (UVP).  Then,  values
were transferred to an Excel spreadsheet for calculation of
means and standard errors.
Statistics: The results were expressed as mean±standard error
of mean (SEM). One-way ANOVA followed by the least
significant  difference  (LSD)-t-test  were  used  to  evaluate
significant  differences.  A  p  value  <0.05  was  considered
statistically significant.
RESULTS
Suppression  of  VEGF165  expression  in  cultured  cells  by
pSilencersiVEGF: To determine whether vector-based VEGF165
targeted  siRNA  expression  system  (pSilencersiVEGF)  could
suppress  the  expression  of  VEGF165,  we  transfected
pSilencersiVEGF  plasmid  to  HUVECs.  Then  the  transfected
cells were further cultured under normoxia (20% O2) and
hypoxia (1% O2) conditions for 24 h, together with null vector
transfected and non-transfected HUVECs (as control). All
these cells were later used for RT–PCR and ELISA analysis.
As  shown  in  Figure  1A,B,  VEGF165  mRNA  levels  in
pSilencersiVEGF transfected cells were dramatically decreased
under both normoxic and hypoxic conditions compared to the
control  cells  (p<0.05),  while  VEGF121  and  VEGF189  were
expressed  to  a  similar  degree  regardless  of  whether
pSilencersiVEGF was applied. Correspondingly, the amount of
VEGF165 protein secreted into the medium of cultured cells
was greatly inhibited after pSilencersiVEGF transfection (Figure
1C), indicating that pSilencersiVEGF could specifically decrease
VEGF165 expression in cultured cells without alteration of
other VEGF isoforms expression under both normoxia and
hypoxia conditions.
Angiographic evaluation of the effect of pSilencersiVEGF on
retinal  neovascularization:  Injection  of  liposome  –
pSilencersiVEGF complexes was performed at P12. Injection of
fluorescein-labeled dextran into left ventricle was done at P17,
followed by retina flatmount. The retinas of room air-raised
mice  revealed  a  normal  capillary  network  without
nonperfusion area and neovascular tufts. However, retinas
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1967from  hyperoxia-exposed  mice  with  pSilencer  null  vector
injection  or  without  any  injection  contained  multiple
neovascular tufts and central nonperfusion areas. In contrast,
fewer neovascular complexes could be found in retinas of
mouse eyes injected with pSilencersiVEGF (Figure 2).
Histological  analysis  of  retinal  neovascularization:
Neovascularization was assessed histologically by counting
the  endothelial  cell  nuclei  anterior  to  the  inner  limiting
membrane.  Retinas  from  hyperoxia-exposed  mice  with
injection of 1000 ng pSilencer null vector or without any
injection  (OIR  model)  were  found  to  contain  multiple
neovascular  tufts  extending  into  the  vitreous.  In  contrast,
fewer  neovascular  complexes  were  observed  in
pSilencersiVEGF-injected retinas (Figure 3). Administration of
1–1000  ng  doses  of  pSilencersiVEGF  resulted  in  a  dose-
dependent decrease in endothelial cell nuclei numbers anterior
to  the  inner  limiting  membrane  (i.e.,  inhibition  of  retinal
neovascularization), with a maximum inhibitory effect of 50%
at the 1000 ng dose (Figure 4).
Inhibition  of  VEGF164  expression  in  murine  retinas  by
pSilencersiVEGF: To determine whether intravitreal injection of
pSilencersiVEGF  could  decrease  VEGF164  expression  in  the
murine retinas, we extracted retinas and assessed them by RT–
PCR and immunohistochemical analysis. Some retinas were
used for RNA extraction and RT–PCR analysis, the others
were  embedded  in  paraffin  and  examined  by
immunohistochemistry. Figure 5A,B show the PCR products
of VEGF isoforms in the murine retinas. Compared to the
control eyes, the level of VEGF164 mRNA was significantly
downregulated in the retinas of hypoxic animals treated with
pSilencersiVEGF, whereas VEGF120 and VEGF188 levels in the
murine retinas remained unchanged after local administration
of pSilencersiVEGF. To confirm the effect of pSilencersiVEGF on
the  expression  level  of  VEGF164  at  the  protein  level,  we
performed  immunohistochemical  studies  to  investigate
VEGF164  expression  patterns  in  the  retinas  of  the  murine
model of OIR. We performed western immunoblotting to
assess the VEGF164 protein level in the retinas of the murine
model of OIR. As shown in Figure 5C,D, local administration
of pSilencersiVEGF significantly decreased expression of VEGF
protein in the murine retinas.
DISCUSSION
Vascular homeostasis is regulated by two counter-balancing
systems:  angiogenic  stimulators  and  angiogenic  inhibitors
[9,10].  Under  pathological  conditions,  such  as  diabetic
Figure  1.  Inhibition  of  VEGF165
expression  in  cultured  cells  by
pSilencersiVEGF A: Shown is a gel image
of a PCR product of VEGF isoforms.
Vascular  endothelial  growth  factor
(VEGF)121,  VEGF165,  and  VEGF189
mRNA levels were determined by RT–
PCR. The lanes are marked as follows:
1) pSilencersiVEGF-transfected cells; 2)
pSilencer null vector-transfected cells;
and  3)  nontransfected  cells.  B:  The
levels  of  VEGF  isoforms  were
quantitated  by  densitometry  and
normalized  by  β-actin  mRNA  levels.
C: VEGF165 levels in the conditioned
media  were  measured  by  ELISA  kits
and normalized to cell counts (1×105).
In  a  comparison  with  control  cells,
hypoxia-induced VEGF165 mRNA and
secreted  VEGF165  expression  were
found to be decreased after transfection
with  pSilencersiVEGF,  while  VEGF121
and  VEGF189  were  expressed  to  a
similar  degree  regardless  of  whether
pSilencersiVEGF  was  administered.
Asterisk indicates p<0.05 compared to
the control cells.
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1968retinopathy  and  retinopathy  of  prematurity,  the  retina
increases  the  production  of  angiogenic  stimulators  and
reduces the production of angiogenic inhibitors, which would
disrupt  the  balance  between  the  positive  and  negative
regulators of angiogenesis [9]. VEGF as major angiogenic
stimulator is upregulated in ocular neovascular diseases [11].
However, due to alternative splicing of mRNA, VEGF has
multiple isoforms. VEGF165 (VEGF164 in mice) is the major
disease-causing isoform in models of neovascular eye disease.
VEGF165  was  found  to  be  more  potent  than  other  VEGF
isoforms  in  inducing  vascular  leakage  and  breakdown  of
blood–retinal barrier [12]. Hence, VEGF165 was selected for
this  study  as  a  target  for  suppressing  retinal
neovascularization.  We  hoped  that  therapy  targeting
VEGF165 in the retina could increase specificity and efficacy
of the treatment.
To  decrease  pathological  VEGF165  upregulation,  we
constructed  a  vector-based  VEGF165  targeted  siRNA
expression  system  (pSilencersiVEGF)  for  our  studies.
pSilencersiVEGF  has  been  shown  to  specifically  inhibit
VEGF165 expression in normoxia-cultured tumor cells [13]. It
has  been  hypothesized  that  sustained  overproduction  of
Figure 2. Angiographic analysis of the effect of pSilencersiVEGF on the murine model of retinal neovascularization. Retinal flatmounts were
examined by fluorescein dextran angiography. A: Shown is a retinal flatmount of mice raised in room air. B: In this retinal flatmount of mice
exposed to hyperoxia, neovascular tufts appear as hyperfluorescence at the junction between the perfused and the nonperfused area. Arrow
points to retinal neovascularization, and star marks an area of nonperfusion. C: In this retinal flatmount of hyperoxia exposed mice injected
with pSilencer null vector, retinal neovascularization and nonperfusion area were not attenuated. D: Shown is a retinal flatmount of hyperoxia-
exposed mice injected with pSilencersiVEGF. The amount of neovascular tufts was markedly reduced and the area of nonperfusion was
diminished.
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1969VEGF  by  hypoxia  retinal  cells  promotes  retinal
neovascularization in several neovascular eye diseases [1].
Consequently,  close  attention  was  paid  to  whether
pSilencersiVEGF could work properly under hypoxia conditions.
VEGF165 was found to be decreased dramatically not only in
the hypoxia cultured cells but also in the hypoxia retinal cells
in the murine animal models, suggesting that hypoxia-induced
VEGF could be abrogated by pSilencersiVEGF under hypoxia
conditions.  We  surmise  that  overproduction  of  VEGF  by
hypoxia retinal cells may also be blocked by pSilencersiVEGF
in  human  neovascular  eye  diseases  such  as  diabetic
retinopathy.
Figure 3. Histological analysis of the effects of treatment with pSilencersiVEGF on ischemia-induced retinal neovascularization. A: Postnatal
day 17 (P17) retina from the eye of a hypoxic mouse injected with 1000 ng pSilencer null vector. Extensive preretinal neovascular loops are
apparent (black arrows). B: P17 retina from the eye of hypoxic mouse injected with 1000 ng pSilencersiVEGF. Preretinal neovascular loops
were not as apparent, suggesting that treatment reduced preretinal neovascularization compared with the pSilencer null vector-injected eye.
The following abbreviations were used in the figure: interlimiting membrane (ILM), ganglion cell layer (GCL), inner nuclear layer (INL),
and outer nuclear layer (ONL).
Figure 4. Dose-dependent inhibition of
retinal  neovascularization  by
pSilencersiVEGF  Administration  of
pSilencersiVEGF at doses 1–1000 ng to
hypoxic  mice  resulted  in  a  dose-
dependent  inhibition  of  retinal
neovascularization  as  measured  by
counting the number of endothelial cell
nuclei  per  section,  with  a  maximum
inhibitory effect of 50% at the 1000 ng
dose.  Asterisk  (*)  indicates  p<0.05
compared to the control eye.
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1970Figure  5.  Suppression  of  vascular
endothelial growth factor expression in
murine  retinas  by  pSilencersiVEGF.
Murine  retinas  were  extracted  and
examined  for  VEGF  level.  One-way
ANOVA  followed  by  the  LSD-t-test
were  used  to  evaluate  significant
differences.  A  p  value  <0.05  was
considered  statistically  significant.
Error bars are standard error of mean
(SEM).  A:  VEGF120,  VEGF164,  and
VEGF188  mRNA  levels  in  murine
retinas  were  examined  by  RT–PCR.
VEGF164 mRNA in murine retinas was
downregulated  after  intravitreal
administration  of  pSilencersiVEGF,
whereas VEGF120 and VEGF188 levels
in murine retinas remained unchanged.
Lanes are marked as follows: 1) room
air-raised mice; 2) murine model with
pSilencersiVEGF  injection;  3)  murine
model  with  pSilencer  null  vector
injection;  and  4)  murine  model  of
oxygen-induced  retinopathy.  B:
Relative  VEGF  isoforms  mRNA
quantification  was  related  to  β-actin
mRNA.  C:  Shown  is  an  immunoblot
assay for VEGF165 protein in the murine
retinas. The total amount of VEGF164
immunosignal  in  murine  retinas  was
reduced  by  pSilencersiVEGF.  The
following  abbreviations  are  used  in
panel  C:  ganglion  cell  layer  (GCL),
inner  nuclear  layer  (INL),  and  outer
nuclear layer (ONL). D: The levels of
VEGF165  were  quantitated  by
densitometry and normalized to β-actin
protein  levels.  Data  are  expressed  as
mean±SEM and were analyzed by one-
way ANOVA followed by LSD-t-test.
The  means  of  groups  3  and  4  are
statistically greater than the means of
groups 1 and 2 (p<0.05).
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1971In the current study, retinal neovascularization in the
murine  model  was  greatly  inhibited  by  1000  ng  of
pSilencersiVEGF.  This  dramatic  decrease  in  retinal
neovascularization  could  be  attributed  to  the  following
reasons.  First,  the  localization  of  plasmids  mediated  by
cationic  liposome  is  close  to  the  site  of  hypoxia-induced
VEGF generation. VEGF164 level in the retinas of the murine
model was found to increase in the inner nuclear layer and
ganglion cell layer in this study, which was consistent with a
previous study [14]. However, cationic liposome has been
confirmed as an effective reagent for retinal gene transfer,
which could carry plasmids into retinal ganglion cells and
retinal  pigment  epithelial  cells  through  the  injection  of
plasmids  and  liposome  complex  into  the  vitreous  [15].
Accordingly, intravitreal injections of pSilencersiVEGF could be
successfully carried into retinal cells, which are in charge of
producing hypoxia-induced VEGF by liposome. Second, the
catalytic  nature  of  RNAi  entered  the  retinal  cells.  Small
hairpin RNA (shRNA) targeting VEGF165 could be generated
and processed into siRNA in these cells. The siRNA targeting
VEGF165  binds  to  the  RNA  induced  silencing  complex
(RISC), which in turn becomes activated. The activated RISC
complex seeks out the VEGF165 mRNA and then splices the
mRNA  at  the  site  of  the  homologous  sequence  [4].
Furthermore,  in  multiple  turnover  kinetic  fashion,  the
activated RISC can seek another VEGF165 mRNA to bind and
destroy. One activated RISC complex can bind and destroy
hundreds of VEGF165 mRNA. Finally, the high efficiency of
pSilencersiVEGF is attributed to the divisional rate of the retinal
cells. The division rate of cells that have taken in siRNA is an
important factor when determining durability of silencing in
cells [16], which leads to dilution of the activated RISC as it
is divided between daughter cells. Because the division rate
of retinal cells is slow, the silencing effect in the cells could
last until upregulation of VEGF in ischemic retina disappears.
In summary, we found that siRNA targeting VEGF165
expressed  from  pSilencersiVEGF  could  decrease  VEGF165
expression in vitro and reduce retinal neovascularization in a
murine  model  of  OIR.  However,  further  experiments  are
necessary to determine whether detrimental side effects will
appear after local administration of pSilencersiVEGF.
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